睿知中国医院研究地图
候选清单

正在招募淋巴瘤早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由苏州大学附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方苏州大学附属第二医院Second Affiliated Hospital of Soochow University苏州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07598578,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Major surgery within 28 days prior to enrollment, or less than 6 weeks after major organ surgery.

    排除标准第 9 条

  3. ECOG performance status 0-2.

    入选标准第 6 条

  4. Hematology: WBC ≥2.0×10⁹/L (≥1.0×10⁹/L if with bone marrow involvement), ANC ≥1.0×10⁹/L (≥0.5×10⁹/L if with bone marrow involvement), PLT ≥50×10⁹/L (≥30×10⁹/L if with bone marrow involvement), HGB ≥7.0 g/dL; no granulocyte growth factor support, platelet or RBC transfusion within 7 days prior to testing.

    入选标准第 9 条

    Liver function: TBIL ≤1.5×ULN (≤3.0×ULN with liver involvement); ALT and AST ≤2.5×ULN (≤5.0×ULN with liver involvement).

    入选标准第 10 条

    Renal function: Serum Cr ≤1.5×ULN.

    入选标准第 11 条

    Coagulation: INR ≤1.5×ULN; PT and APTT ≤1.5×ULN (unless on anticoagulant therapy with PT/APTT within therapeutic range at screening).

    入选标准第 12 条

  5. At least one measurable or evaluable lesion according to the Lugano 2014 classification. Measurable lesion: nodal lesion with longest diameter >1.5 cm and shortest diameter >1.0 cm on CT/PET-CT or MRI; or extranodal lesion with longest diameter >1.0 cm. Evaluable lesion: nodal or extranodal focal uptake on 18F-FDG/PET higher than liver with PET and/or CT features consistent with lymphoma.

    入选标准第 5 条

  6. History of other malignancies within the past 5 years, except for those treated with curative intent (e.g., basal cell carcinoma of the skin, carcinoma in situ).

    排除标准第 1 条

    Known history of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).

    排除标准第 5 条

  7. Pregnant or lactating women, and subjects of childbearing potential unwilling to use effective contraception.

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07598578,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥18 years and ≤75 years, male or female.
  2. Histologically confirmed peripheral T-cell lymphoma (PTCL) by the investigating center, including: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALK-negative or ALK-positive); angioimmunoblastic T-cell lymphoma; enteropathy-associated T-cell lymphoma; NK/T-cell lymphoma; and other PTCL subtypes deemed eligible by the investigator.
  3. Relapsed or refractory disease after at least one prior line of systemic therapy. Relapse is defined as disease recurrence after complete response (CR) or progression after partial response (PR) or stable disease (SD). Refractory disease is defined as progressive disease (PD) after 2 cycles of therapy, or SD after 4 cycles of therapy, or failure to achieve response after adequate last-line therapy (e.g., at least 2-3 cycles of systemic chemotherapy without remission), or progression during treatment.
  4. Patients considered ineligible for autologous hematopoietic stem cell transplantation by the investigator, or those who refuse such treatment.
  5. At least one measurable or evaluable lesion according to the Lugano 2014 classification. Measurable lesion: nodal lesion with longest diameter >1.5 cm and shortest diameter >1.0 cm on CT/PET-CT or MRI; or extranodal lesion with longest diameter >1.0 cm. Evaluable lesion: nodal or extranodal focal uptake on 18F-FDG/PET higher than liver with PET and/or CT features consistent with lymphoma.
  6. ECOG performance status 0-2.
  7. Life expectancy ≥3 months.
  8. Adequate organ and bone marrow function defined as:
  9. Hematology: WBC ≥2.0×10⁹/L (≥1.0×10⁹/L if with bone marrow involvement), ANC ≥1.0×10⁹/L (≥0.5×10⁹/L if with bone marrow involvement), PLT ≥50×10⁹/L (≥30×10⁹/L if with bone marrow involvement), HGB ≥7.0 g/dL; no granulocyte growth factor support, platelet or RBC transfusion within 7 days prior to testing.
  10. Liver function: TBIL ≤1.5×ULN (≤3.0×ULN with liver involvement); ALT and AST ≤2.5×ULN (≤5.0×ULN with liver involvement).
  11. Renal function: Serum Cr ≤1.5×ULN.
  12. Coagulation: INR ≤1.5×ULN; PT and APTT ≤1.5×ULN (unless on anticoagulant therapy with PT/APTT within therapeutic range at screening).
  13. Thyroid function: TSH, FT4, and FT3 within ±10% of normal range (Note: TSH abnormalities due to non-autoimmune causes are acceptable).
  14. Cardiac function: Left ventricular ejection fraction ≥50%, no organic arrhythmia, no significant abnormalities in cardiac enzymes.

排除标准:Exclusion Criteria:

  1. History of other malignancies within the past 5 years, except for those treated with curative intent (e.g., basal cell carcinoma of the skin, carcinoma in situ).
  2. Patients with significant dysfunction of major organs.
  3. Known involvement of central nervous system (CNS) lymphoma.
  4. History of active bleeding or newly diagnosed thrombotic disease, or those with bleeding tendency receiving anticoagulant therapy.
  5. Known history of Human Immunodeficiency Virus (HIV) infection and/or Acquired Immunodeficiency Syndrome (AIDS).
  6. Patients with active chronic hepatitis B or active hepatitis C.
  7. Systemic corticosteroid therapy or other immunosuppressive therapy required for any condition within 14 days prior to initiation of study treatment.
  8. Active autoimmune disease requiring systemic treatment within the past two years. Patients with autoimmune diseases not requiring systemic treatment in the past two years may be enrolled.
  9. Major surgery within 28 days prior to enrollment, or less than 6 weeks after major organ surgery.
  10. Administration of live attenuated vaccines within 4 weeks prior to enrollment or planned during the study period (influenza vaccines excluded).
  11. Pregnant or lactating women, and subjects of childbearing potential unwilling to use effective contraception.
  12. Psychiatric disorders or individuals unable to provide informed consent.
  13. Active infection, except for tumor-related B-symptom fever.
  14. Poorly controlled cardiac symptoms or diseases, including:
  15. Any other condition deemed by the investigator to make the subject unsuitable for study participation.

引自 ClinicalTrials.gov, NCT07598578, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07598578,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07598578